ABX464-907
10 evidence topics · 3 sources
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-907” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/09/2024” |
| End of trial | “End of trial 14/10/2025” |
Study design
Additional Phase 1 trials described in the Form 20-F
Eligibility criteria
Participant type and age in the EU register
| Field | Register entry |
|---|---|
| Participants type | “Participants type Healthy volunteers, Patients” |
| Age range | “Age range 18-64 years, 65+ years” |
Treatment
Multiple oral doses of obefazimod
Study outcomes
Rationale for using Obefazimod pharmacokinetics in renal impairment as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-907 has only an EU register record. The register gives the title, the dates (9 September 2024 to 14 October 2025), one site in Germany, and 48 planned participants, who include patients and healthy volunteers aged 18 years or older. The Form 20-F does not name this trial among the completed Phase 1 trials. The categories of renal impairment, the dose, the number per group, the inclusion of participants on dialysis, and the endpoints are not public, and the summary of results is deferred until 14 April 2028. No exposure or safety result is available to inform dosing in renal impairment.